RITONAVIR
Impaired Liver Function
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Small moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Impaired Liver Function cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ModraDoc006 Modra Pharmaceuticals | Phase 1 | CC |
Same molecule, other indications
RITONAVIR is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →